Skip to content

Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

A Multicenter, Observational Study for the Clinical Roadmap and Prognosis of Pulmonary Artery Sarcoma.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06165718
Enrollment
120
Registered
2023-12-11
Start date
2022-12-31
Completion date
2025-06-30
Last updated
2023-12-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Artery Sarcoma

Brief summary

This is an observational study in which patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Detailed description

This is an observational study covering mainland China, and patients with pulmonary artery sarcoma were followed up for at least 36 months and survival was investigated.

Interventions

None listed

Sponsors

The First Affiliated Hospital of Guangzhou Medical University
CollaboratorOTHER
Beijing Chao Yang Hospital
CollaboratorOTHER
Shanghai Pulmonary Hospital, Shanghai, China
CollaboratorOTHER
Sir Run Run Shaw Hospital
CollaboratorOTHER
Beijing Anzhen Hospital
CollaboratorOTHER
China-Japan Friendship Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Computed tomography pulmonary angiography indicated that there were intraluminal defects * Malignant histopathology was sarcoma * Informed consent form was signed

Exclusion criteria

* Life expectancy was less than 3 months due to diseases other than pulmonary artery sarcoma * Expected inability to complete follow-up

Design outcomes

Primary

MeasureTime frameDescription
Progression-free survival36 monthsTime to death or disease progression

Secondary

MeasureTime frameDescription
Overall survival36 monthsTime to death
Postoperative survival36 monthsTime from surgery to death

Countries

China

Contacts

Primary ContactWanmu Xie
xiewanmu@126.com+86 15611734410

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026